352 related articles for article (PubMed ID: 14603548)
21. Treatment of multiple myeloma: 2009 update.
Prescrire Int; 2009 Dec; 18(104):263-6. PubMed ID: 20025098
[TBL] [Abstract][Full Text] [Related]
22. Nontraditional cytotoxic therapies for relapsed/refractory multiple myeloma.
Hussein MA
Oncologist; 2002; 7 Suppl 1():20-9. PubMed ID: 11961206
[TBL] [Abstract][Full Text] [Related]
23. Clinical management of myeloma--state of the art.
Harousseau JL
Cancer Treat Rev; 2010 May; 36 Suppl 2():S1-2. PubMed ID: 20472182
[TBL] [Abstract][Full Text] [Related]
24. Therapy strategies for multiple myeloma: current status.
Gisslinger H; Kees M
Wien Klin Wochenschr; 2003 Aug; 115(13-14):451-61. PubMed ID: 13677263
[TBL] [Abstract][Full Text] [Related]
25. [Treatment with a proteasome inhibitor, bortezomib, for thalidomide-resistant multiple myeloma].
Takatoku M; Noborio-Hatano K; Takahashi S; Kikuchi S; Mori M; Muroi K; Komatsu N; Ozawa K
Rinsho Ketsueki; 2004 Feb; 45(2):144-8. PubMed ID: 15045823
[TBL] [Abstract][Full Text] [Related]
26. Treatment paradigms for the newly diagnosed patient with multiple myeloma.
Greipp P
Semin Hematol; 2005 Oct; 42(4 Suppl 4):S16-21. PubMed ID: 16344097
[TBL] [Abstract][Full Text] [Related]
27. Future drug developments in multiple myeloma: an overview of novel lenalidomide-based combination therapies.
Morgan G
Blood Rev; 2010 Nov; 24 Suppl 1():S27-32. PubMed ID: 21126634
[TBL] [Abstract][Full Text] [Related]
28. Novel agents for relapsed and/or refractory multiple myeloma.
Thomas SK; Richards TA; Weber DM
Cancer J; 2009; 15(6):485-93. PubMed ID: 20010168
[TBL] [Abstract][Full Text] [Related]
29. Multiple myeloma: improved outcomes with new therapeutic approaches.
Eshaghian S; Berenson JR
Curr Opin Support Palliat Care; 2012 Sep; 6(3):330-6. PubMed ID: 22871979
[TBL] [Abstract][Full Text] [Related]
30. New agents and approaches in the treatment of multiple myeloma.
Anderson KC
Clin Adv Hematol Oncol; 2003 Mar; 1(3):151-2. PubMed ID: 16224394
[No Abstract] [Full Text] [Related]
31. Proteasome inhibitor holds promise for patients with refractory multiple myeloma.
Expert Rev Anticancer Ther; 2001 Dec; 1(4):509-10. PubMed ID: 12113081
[No Abstract] [Full Text] [Related]
32. [Proteasome inhibitors for multiple myeloma].
Yano H; Iida S
Nihon Rinsho; 2007 Jan; 65 Suppl 1():601-4. PubMed ID: 17476759
[No Abstract] [Full Text] [Related]
33. Therapeutic use of immunomodulatory drugs in the treatment of multiple myeloma.
Raje N; Hideshima T; Anderson KC
Expert Rev Anticancer Ther; 2006 Sep; 6(9):1239-47. PubMed ID: 17020458
[TBL] [Abstract][Full Text] [Related]
34. Targeted therapy in multiple myeloma.
Chng WJ; Lau LG; Yusof N; Mow BM
Cancer Control; 2005 Apr; 12(2):91-104. PubMed ID: 15855892
[TBL] [Abstract][Full Text] [Related]
35. Management of older patients with multiple myeloma.
Gay F; Palumbo A
Blood Rev; 2011 Mar; 25(2):65-73. PubMed ID: 21295387
[TBL] [Abstract][Full Text] [Related]
36. High complete remission rate and durable remissions achieved with rational use of autologous stem-cell transplantation, thalidomide maintenance, and non-myeloablative allogeneic transplantation in patients with multiple myeloma.
Oyan B; Koc Y; Ozdemir E; Kars A; Turker A; Tekuzman G; Kansu E
Clin Transplant; 2009; 23(6):839-47. PubMed ID: 20447186
[TBL] [Abstract][Full Text] [Related]
37. Proteasome inhibition and its clinical prospects in the treatment of hematologic and solid malignancies.
Ludwig H; Khayat D; Giaccone G; Facon T
Cancer; 2005 Nov; 104(9):1794-807. PubMed ID: 16178003
[TBL] [Abstract][Full Text] [Related]
38. Beyond single-agent bortezomib: combination regimens in relapsed multiple myeloma.
Richardson PG; Mitsiades C; Ghobrial I; Anderson K
Curr Opin Oncol; 2006 Nov; 18(6):598-608. PubMed ID: 16988581
[TBL] [Abstract][Full Text] [Related]
39. Novel biologically based therapies for Waldenstrom's macroglobulinemia.
Mitsiades CS; Mitsiades N; Richardson PG; Treon SP; Anderson KC
Semin Oncol; 2003 Apr; 30(2):309-12. PubMed ID: 12720159
[TBL] [Abstract][Full Text] [Related]
40. New developments in the treatment of patients with multiple myeloma.
Minnema MC; van der Spek E; van de Donk NW; Lokhorst HM
Neth J Med; 2010 Jan; 68(1):24-32. PubMed ID: 20103818
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]